NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT00876486,Evaluate the Efficacy and Safety of Genexol®-PM Compared to Genexol® in Recurrent or Metastatic Breast Cancer,https://clinicaltrials.gov/study/NCT00876486,,COMPLETED,Phase III trial to evaluate the efficacy and safety of Genexol®-PM compared to Genexol® in subjects with recurrent or metastatic breast cancer.,NO,Breast Cancer,DRUG: Genexol-PM®|DRUG: Genexol®,"Objective Response Rate, Evaluate the efficacy of Genexol®-PM versus Genexol® in subjects with recurrent or metastatic breast cancer based on Objective Response Rate., 6 months","Overall Survival, Progress Free Survival, Time to Tumor Progression, Duration of Overall Response, To evaluate the efficacy of Genexol®-PM relative to Genexol® as measured by Overall Survival, Progress Free Survival, Time to Tumor Progression, Duration of Overall Response., Event driven|Safety and toxicity, To compare the safety and toxicity of Genexol®-PM with those of Genexol®, Throughout study",,Samyang Biopharmaceuticals Corporation,,FEMALE,"ADULT, OLDER_ADULT",PHASE3,213,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,GPMBC301,2008-12,2013-02,2013-11,2009-04-06,,2017-05-01,"National Cancer Center, Goyang-si, Gyeonggi-do, Korea, Republic of",
